News

The funding round was led by Enavate Sciences, a portfolio company created by Patient Square Capital. The round also saw participation of Gaingels, along with other undisclosed investors.

Applying Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology, the partnership intends to develop intravitreal AAV capsids matching a capsid profile defined by Roche. As per the

Under the two-year sponsored research alliance, the companies will work to identify new drug candidates that enable inhibition of two proteins, Bax and Bak. These proteins are integral

Under the terms of the deal, the company will be responsible for the supply of 2.5 million additional doses of liquid frozen Jynneos vaccines. The latest move follows

Discovered and developed by SK Biopharmaceuticals and SK life science, cenobamate is an anti-seizure medication (ASM). It is already approved and available in Europe and the US to treat

The drug is approved and available in the US and Europe to treat partial-onset seizures in adults. As per the terms of the agreement, SK Biopharmaceuticals has granted

The therapy, which has been studied in various Phase I and II clinical trials, demonstrated the potential to amplify T cells across the subsets, improve the immune system,

Orion Biotechnology Canada is a drug discovery company targeting earlier undruggable GPCRs. A biotech firm, Peptilogics is into engineering peptide therapeutics by bringing together computation and biology to

New investors Sands Capital and Vivo Capital have jointly led the financing round, which has also seen participation from new investor Dreavent 6. Sofinnova Partners, New York City